# A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors

Source: https://onco.cc/trials/nct06336148/  
OnCo record `nct06336148` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of ACTM-838 run by Actym Therapeutics, Inc., terminated.

## Summary

A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors is a phase 1 interventional study registered as NCT06336148 by Actym Therapeutics, Inc., with 10 participants enrolled, started 2024-06-05. Conditions recorded: Solid Tumor. Interventions recorded: ACTM-838.

## Fields

- Kind: Trial
- Status: historic
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06336148
- Phase: 1
- Setting: A Phase 1a/1b Open-label, Dose-Escalation and Expansion Study of ACTM-838 as a Single Agent in Patients With Advanced Solid Tumors
- Sponsor: Actym Therapeutics, Inc.
- Enrolled: 10

## Sources

- ClinicalTrials.gov NCT06336148: https://clinicaltrials.gov/study/NCT06336148

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [ACTM-838](https://onco.cc/drugs/actm-838/)
- companies: [Actym Therapeutics](https://onco.cc/companies/actym-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct06336148.json